Oxford, AstraZeneca Vaccine’s Strong Response in Elderly Confirmed in Review
LONDON—A Covid-19 vaccine being developed by the University of Oxford and AstraZeneca PLC showed promising immune responses in elderly and older adults, with fewer serious side effects than in younger volunteers, according to a just-published interim analysis previewed in late October.
伦敦-牛津大学(University Of Oxford)和阿斯利康(AstraZeneca PLC)正在开发的新冠肺炎疫苗在老年人和老年人中显示出良好的免疫反应，严重副作用比年轻志愿者少，10月底预览的一份中期分析报告显示。
The data from that preview have now been peer reviewed. The results were published Thursday in the Lancet medical journal, providing a stamp of approval for the earlier findings. The data were based on earlier, Phase Two human trials of the vaccine.
AstraZeneca and Oxford have yet to release later-stage, or Phase Three, trial data demonstrating the vaccine’s overall efficacy in fighting Covid-19. Those trials continue.
Drugmakers of two rival vaccine candidates—one from Pfizer Inc. and Germany’s BioNTech SE and another from Moderna Inc. —have each disclosed efficacy rates of more than 90%, higher than many had expected from vaccines developed so quickly. The vaccines’ full safety data hasn’t yet been published.
两个竞争对手候选疫苗的制药商--其中一个来自辉瑞公司(Pfizer Inc.)。德国的BioNTech SE和另一家来自现代公司的公司。-每一家公司都披露了90%以上的有效率，高于许多人对如此快速开发的疫苗的预期。疫苗的全部安全性数据尚未公布。
People involved in the Oxford-AstraZeneca vaccine have said they expect their efficacy data, from ongoing late-stage trials, in the coming weeks. Unlike the Pfizer and Moderna programs, which rely on a new vaccine technology called messenger RNA, the vaccine developed by AstraZeneca and Oxford represents a more traditional approach.
参与牛津-阿斯利康(Oxford-AstraZeneca)疫苗研发的人士表示，他们预计未来几周将公布正在进行的后期试验的疗效数据。与辉瑞(Pfizer)和摩登那(Modern Na)项目不同，后者依赖一种名为信使RNA(Messenger RNA)的新疫苗技术，而阿斯利康(AstraZeneca)和牛津大学(Oxford)开发的疫苗代表了一种更。
AstraZeneca has committed to making the vaccine at greater volumes across a wider geographic footprint than its Western peers. It has also promised to deliver doses at no profit during the pandemic, and continuing afterward for poorer countries. All that has heightened anticipation of clinical results for the AstraZeneca vaccine, with hopes it can complement rollouts of other shots in parts of the world that might not have immediate access to Pfizer’s and Moderna’s shots.
The data describing the vaccine’s effect on older people has also taken on outsize importance, since this group is especially vulnerable to serious illness or death from the virus.
In the peer-reviewed study of the vaccine, healthy adults aged 56 and older showed similar positive immune responses to younger trial participants. The oldest adults involved—with an average age of 73-74 years—showed milder adverse reactions, according to early results published Thursday.
Governments are expected to give priority to older adults in rollouts of vaccines, which could start in limited quantities before the end of this year. Scientists have said they expect different age groups to react differently to different vaccines—a big reason why they expect multiple vaccines to be necessary to protect all ages in the coming months and years.
The Oxford vaccine spurred trial participants’ immune systems to find and attack cells infected with the virus, and following a second, booster shot was effective in attacking the virus in the bloodstream, according to the interim results. Those positive outcomes were present in all age groups given low and standard doses. Some participants received just one shot, while others got a booster after 28 days. The early-stage study involved 560 healthy adults, including 240 people older than 70 years. Most were white nonsmokers.
The continuing late-stage trials of the vaccine will show broader results for safety and efficacy, including in older adults with underlying health conditions, and from a wider range of backgrounds, countries and ethnicities of all ages, researchers said.
“Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections,” said Andrew Pollard, an Oxford professor who is the lead author of the study.
The most common side effects were pain at the injection site, fatigue, headache, feverishness and muscle pain. Fewer people aged 70 or over experienced those temporary symptoms, compared with younger trial participants, researchers said.